The most played episodes among Podcast App listeners.

1. 1
   Number 1: Revolution Medicines CEO Dr. Mark Goldsmith: Daraxonrasib dream to reality

   Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib. Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes. Keypoints: Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases. The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine. Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients. Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes. Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place. Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease. We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care. Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research! #PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers

   September 21, 2026·27min
   Play
2. 2
   Number 2: Diffuse Large B-cell Lymphoma (DLBCL) Treatment Algorithm: Dr. Mazyar Shadman

   In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center. We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies. Key topics covered in this episode: Frontline treatment options for DLBCL The role of polatuzumab in early-stage disease Treatment paradigms for advanced-stage DLBCL CAR T-cell therapy: who should receive it and when The importance of community and tertiary care partnerships in improving patient access to innovative therapies Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

   September 22, 2026·22min
   Play
3. 3
   Number 3: Camizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6

   Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial. We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life. Key topics covered in this episode: Overview of the SERENA-6 trial and its findings The role of ESR1 mutations in treatment resistance The efficacy and safety profile of camizestrant Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice Management of side effects, including bradycardia and QT prolongation Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers

   September 16, 2026·21min
   Play
4. 4
   Number 4: Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann

   Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute. Join us as we explored: The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs The importance of spleen reduction and its correlation with patient outcomes and survival Insights into the side effect profiles of various treatments and the future of myelofibrosis management Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

   September 07, 2026·25min
   Play
5. 5
   Number 5: SURPASS-ET: FDA Approval of Ropeginterferon alfa-2b in Essential Thrombocythemia (ET)

   Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV). The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea. Key topics covered in this episode included: Overview of the SURPASS-ET study and its significance Efficacy and tolerability of ropeginterferon alfa-2b in ET Side effect profiles of ropeginterferon alfa-2b vs anagrelide The importance of monitoring JAK2 allele burden and its clinical relevance Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics! #EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers

   September 14, 2026·23min
   Play